MS 551 | CAS#130656-51-8

MS 551
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 534791

CAS#: 130656-51-8

Description: MS 551 is a bioactive chemical.

Chemical Structure

MS 551

CAS# 130656-51-8

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 534791
Name: MS 551
CAS#: 130656-51-8
Chemical Formula: C19H28ClN5O5
Exact Mass: 441.18
Molecular Weight: 441.913
Elemental Analysis: C, 51.64; H, 6.39; Cl, 8.02; N, 15.85; O, 18.10

Price and Availability

Size	Price	Availability
5mg	USD 250	2 Weeks
25mg	USD 510	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: MS 551; MS551; MS-551

IUPAC/Chemical Name: 2,4(1H,3H)-Pyrimidinedione, 6-((2-((2-hydroxyethyl)(3-(4-nitrophenyl)propyl)amino)ethyl)amino)-1,3-dimethyl-, monohydrochloride

InChi Key: YPVGGQKNWAKOPX-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H27N5O5.ClH/c1-21-17(14-18(26)22(2)19(21)27)20-9-11-23(12-13-25)10-3-4-15-5-7-16(8-6-15)24(28)29;/h5-8,14,20,25H,3-4,9-13H2,1-2H3;1H

SMILES Code: O=C1N(C)C(C=C(NCCN(CCO)CCCC2=CC=C([N+]([O-])=O)C=C2)N1C)=O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	Nifekalant hydrochloride (MS-551), a class III antiarrhythmic agent, is a IKr potassium channel blocker with an IC50 of 10 µM.
In vitro activity:	MS-551 in the range from 1 microM to 100 microM produced a concentration-dependent reduction of the open probability of the ATP-sensitive potassium channel, with an apparent ED50 of 30 microM. This reduced channel activity was due to a smaller number of channel openings per unit time, and the average duration of each opening of the channel was unaffected. Reference: Pharmacol Toxicol. 1995 Jul;77(1):65-70. https://pubmed.ncbi.nlm.nih.gov/8532614/
In vivo activity:	The antiarrhythmic and haemodynamic effects of three class III antiarrhythmic drugs, MS-551, sematilide and dofetilide, were examined in the coronary artery, ligation-reperfusion model of pentobarbitone-anaesthetized rats, a species deficient in functional cardiac IK. Before coronary ligation, 3 and 10 mg kg-1 MS-551 decreased the heart rate by 6% (P < 0.01) and 12% (P < 0.01), and increased mean arterial pressure (MAP) by 14% (P < 0.05) and 33% (P < 0.01), respectively. MS-551 at 3 and 10 mg kg-1, reduced the incidence of lethal VF to 50% and 20% (P < 0.05). Reference: Br J Pharmacol. 1996 Nov;119(5):937-42. https://pubmed.ncbi.nlm.nih.gov/8922743/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	125.0	282.86

Preparing Stock Solutions

The following data is based on the product molecular weight 441.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Suzuki K, Furukawa T, Koyama Y, Sagawa T, Nishimura M, Yamanaka M. Concentration-dependent block of sodium current in guinea pig ventricular myocytes by a class III antiarrhythmic agent, MS-551. J Cardiovasc Pharmacol. 1998 Nov;32(5):819-25. doi: 10.1097/00005344-199811000-00019. PMID: 9821857. 2. Martin DK, Nakaya Y, Wyse KR, Bursill JA, West PD, Campbell TJ. Inhibition of ATP-sensitive potassium channels in cardiac myocytes by the novel class III antiarrhythmic agent MS-551. Pharmacol Toxicol. 1995 Jul;77(1):65-70. doi: 10.1111/j.1600-0773.1995.tb01915.x. PMID: 8532614. 3. Chen J, Komori S, Li B, Tamura K, Hashimoto K. IK independent class III actions of MS-551 compared with sematilide and dofetilide during reperfusion in anaesthetized rats. Br J Pharmacol. 1996 Nov;119(5):937-42. doi: 10.1111/j.1476-5381.1996.tb15762.x. PMID: 8922743; PMCID: PMC1915953. 4. Kamiya J, Ishii M, Katakami T. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia. Jpn J Pharmacol. 1992 Feb;58(2):107-15. doi: 10.1254/jjp.58.107. PMID: 1507517.
In vitro protocol:	1. Suzuki K, Furukawa T, Koyama Y, Sagawa T, Nishimura M, Yamanaka M. Concentration-dependent block of sodium current in guinea pig ventricular myocytes by a class III antiarrhythmic agent, MS-551. J Cardiovasc Pharmacol. 1998 Nov;32(5):819-25. doi: 10.1097/00005344-199811000-00019. PMID: 9821857. 2. Martin DK, Nakaya Y, Wyse KR, Bursill JA, West PD, Campbell TJ. Inhibition of ATP-sensitive potassium channels in cardiac myocytes by the novel class III antiarrhythmic agent MS-551. Pharmacol Toxicol. 1995 Jul;77(1):65-70. doi: 10.1111/j.1600-0773.1995.tb01915.x. PMID: 8532614.
In vivo protocol:	1. Chen J, Komori S, Li B, Tamura K, Hashimoto K. IK independent class III actions of MS-551 compared with sematilide and dofetilide during reperfusion in anaesthetized rats. Br J Pharmacol. 1996 Nov;119(5):937-42. doi: 10.1111/j.1476-5381.1996.tb15762.x. PMID: 8922743; PMCID: PMC1915953. 2. Kamiya J, Ishii M, Katakami T. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia. Jpn J Pharmacol. 1992 Feb;58(2):107-15. doi: 10.1254/jjp.58.107. PMID: 1507517.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Cheng J, Kamiya K, Kodama I, Toyama J. Differential effects of MS-551 and E-4031 on action potentials and the delayed rectifier K+ current in rabbit ventricular myocytes. Cardiovasc Res. 1996 Jun;31(6):963-74. PMID: 8759253.

2: Sato R, Koumi S, Hisatome I, Takai H, Aida Y, Oyaizu M, Karasaki S, Mashiba H, Katori R. A new class III antiarrhythmic drug, MS-551, blocks the inward rectifier potassium channel in isolated guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1995 Jul;274(1):469-74. PMID: 7616432.

3: Isomoto S, Konoe A, Centurion OA, Hayano M, Kaibara M, Hirata T, Yano K. Electrophysiological effects of MS-551 in humans: a class III antiarrhythmic agent. Pacing Clin Electrophysiol. 1995 Nov;18(11):2022-7. doi: 10.1111/j.1540-8159.1995.tb03863.x. PMID: 8552516.

4: Sen L, Cui G, Sakaguchi Y, Singh BN. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs. J Pharmacol Exp Ther. 1998 May;285(2):687-94. PMID: 9580614.

5: Chen J, Komori S, Li B, Tamura K, Hashimoto K. IK independent class III actions of MS-551 compared with sematilide and dofetilide during reperfusion in anaesthetized rats. Br J Pharmacol. 1996 Nov;119(5):937-42. doi: 10.1111/j.1476-5381.1996.tb15762.x. PMID: 8922743; PMCID: PMC1915953.

6: Kamiya J, Ishii M, Katakami T. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia. Jpn J Pharmacol. 1992 Feb;58(2):107-15. doi: 10.1254/jjp.58.107. PMID: 1507517.

7: Nakaya H, Tohse N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol. 1993 May;109(1):157-63. doi: 10.1111/j.1476-5381.1993.tb13546.x. PMID: 7684298; PMCID: PMC2175592.

8: Chowdhury A, Fernandes B, Melhuish TM, White LD. Antiarrhythmics in Cardiac Arrest: A Systematic Review and Meta-Analysis. Heart Lung Circ. 2018 Mar;27(3):280-290. doi: 10.1016/j.hlc.2017.07.004. Epub 2017 Aug 23. PMID: 28988724.

9: Friedrichs GS, Chi L, Gralinski MR, Black SC, Basler GC, Mu DX, Pewitt SR, Johnson CR, Lucchesi BR. MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death. J Cardiovasc Pharmacol. 1995 Feb;25(2):314-23. doi: 10.1097/00005344-199502000-00018. PMID: 7752658.

10: Naitoh N, Tagawa M, Yamaura M, Taneda K, Furushima H, Aizawa Y. Comparison of electrophysiologic effects of intravenous E-4031 and MS-551, novel class III antiarrhythmic agents, in patients with ventricular tachyarrhythmias. Jpn Heart J. 1998 Jul;39(4):457-67. doi: 10.1536/ihj.39.457. PMID: 9810296.

11: Long B, Koyfman A. Best Clinical Practice: Emergency Medicine Management of Stable Monomorphic Ventricular Tachycardia. J Emerg Med. 2017 Apr;52(4):484-492. doi: 10.1016/j.jemermed.2016.09.010. Epub 2016 Oct 15. PMID: 27751700.

12: Uwabe K, Endo M, Nishida H, Tomizawa Y, Koyanagi H, Ohnishi S, Kasanuki H. [The effect of MS-551 on two VT/Vf patients in CABG: a case report]. Kyobu Geka. 1998 Feb;51(2):108-11. Japanese. PMID: 9492458.

13: Xue Y, Yamada C, Aye NN, Hashimoto K. MS-551 and KCB-328, two class III drugs aggravated adrenaline-induced arrhythmias. Br J Pharmacol. 1998 Aug;124(8):1712-8. doi: 10.1038/sj.bjp.0701987. PMID: 9756388; PMCID: PMC1565555.

14: Friedrichs GS, Chi L, Black SC, Manley PJ, Lucchesi BR. Antiarrhythmic agent, MS-551, protects against pinacidil + hypoxia-induced ventricular fibrillation in Langendorff-perfused rabbit isolated heart. J Cardiovasc Pharmacol. 1994 Jan;23(1):120-6. doi: 10.1097/00005344-199401000-00017. PMID: 7511723.

15: Suzuki K, Furukawa T, Koyama Y, Sagawa T, Nishimura M, Yamanaka M. Concentration-dependent block of sodium current in guinea pig ventricular myocytes by a class III antiarrhythmic agent, MS-551. J Cardiovasc Pharmacol. 1998 Nov;32(5):819-25. doi: 10.1097/00005344-199811000-00019. PMID: 9821857.

16: Naitoh N, Taneda K, Tagawa M, Furushima H, Yamaura M, Aizawa Y. Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle. Jpn Heart J. 1998 May;39(3):297-305. doi: 10.1536/ihj.39.297. PMID: 9711181.

17: Yamada A, Motomura S, Hashimoto K. Comparison of direct negative chronotropic and positive inotropic effects of sematilide to those of E-4031 and MS-551 and the reverse frequency-dependent prolongation of cardiac refractoriness of sematilide. J Cardiovasc Pharmacol. 1996 Jan;27(1):159-66. doi: 10.1097/00005344-199601000-00025. PMID: 8656651.

18: Kondoh K, Hashimoto H, Nishiyama H, Umemura K, Ozaki T, Uematsu T, Nakashima M. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model. J Cardiovasc Pharmacol. 1994 Apr;23(4):674-80. doi: 10.1097/00005344-199404000-00024. PMID: 7516022.

19: Tanabe T, Iwamoto T, Iwata O, Aikawa M, Kusuzaki S, Handa S, Shinozaki Y, Mori H. Electrophysiologic and blood-flow responses in the endocardium and epicardium to disopyramide and MS-551 during myocardial ischemia in the dog. J Cardiovasc Pharmacol. 1999 Aug;34(2):275-86. doi: 10.1097/00005344-199908000-00014. PMID: 10445680.

20: Furutani K, Tsumoto K, Chen IS, Handa K, Yamakawa Y, Sack JT, Kurachi Y. Facilitation of IKr current by some hERG channel blockers suppresses early afterdepolarizations. J Gen Physiol. 2019 Feb 4;151(2):214-230. doi: 10.1085/jgp.201812192. Epub 2019 Jan 23. PMID: 30674563; PMCID: PMC6363420.

Your view history

MS 551 featured